Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3796)	5/15/2001 3:36:31 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Never understood the logic of why a rate cut would be bad for biotechs. Basically biotechs are highly driven by liquidity (look at the run up to the March 200 high followed by the crash as the money supply ballooned through the Y2K scare and then sharply contracted again). It is true that the top tier biotechs sitting on their billions in cash are slightly adversely affected by a rate cut pushing down their near-term earnings, but that's about it on the negative side. On another issue, have people noticed Adelor? (ADLR). Clever me was going to buy this when the lockup got released and the stock plummeted. Only problem was that the stock instead plummeted early and then recovered sharply on lockup release on massive volume - it's up from under $14 to around $19 in just a few days. So I missed it altogether... Peter